ATYR: מחיר למכירות aTyr Pharma Inc
The P/S ratio history demonstrates the market transparency of aTyr Pharma, Inc. (ATYR), with the 78.50 mark reflecting the latest data. aTyr Pharma, Inc. (ATYR) focuses on developing protein immunotherapy for rare lung pathologies, leveraging its patent portfolio. However, geopolitical tensions and logistical complexities could hinder the procurement of ingredients. High demand in specialized centers provides potential for the commercialization of new drugs.
פילוחי מדדים ואנליטיקה של חברת aTyr (ATYR)
An objective business valuation is critical for capital protection amid uncertainty. The P/S ratio compares market capitalization to annual sales volume, determining the premium the market is willing to pay per unit of revenue. By analyzing the current P/S level, an investor assesses the degree to which an asset is overbought. For aTyr Pharma, Inc. (ATYR), this metric reflects expectations regarding the lack of alternatives for fibrous disease therapies and long-term margin stability.
